| | Webinar: Digitize Remote Site Monitoring with Box Tuesday, October 13 | 2pm ET / 11am PT Fierce Pharma is teaming up with Box to discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing. Accelerate R&D processes across the value chain, maintain GxP compliance and reduce your overall IT footprint. Register Today! |
Pfizer CEO Bourla, 'disappointed' by COVID vaccine rhetoric, warns politics could threaten uptake Azar pushes back on congressional concerns of political interference in COVID-19 vaccine approval Moderna CEO says coronavirus vaccine won't be ready for FDA till late November: FT LabCorp receives FDA green light for a new type of COVID-19 test using fewer reagents Gilead Sciences takes back remdesivir distribution as demand drops Biopharma roundup: White House objects to FDA vaccine rules; Would Trump be treated with Regeneron or Lilly antibodies? Healthcare roundup: Healthcare workers should be among the first vaccinated, National Academies says in new report Perlmutter steps down as Merck R&D lead as early research chief Li steps in GSK's ex-vaccine, pharma lead jumps ship to run G1 Therapeutics Featured Story | By Eric Sagonowsky Pfizer could be just weeks away from reporting early phase 3 data for its coronavirus vaccine—a remarkable feat amid a global pandemic—but as the company nears its goal, politics is increasingly threatening the process, CEO Albert Bourla warned. read more |
| |
|---|
|
Top Stories By Robert King HHS Secretary Alex Azar denied there will be political interference to approve a COVID-19 vaccine before it is ready, sparing with House lawmakers over a new report. read more By Eric Sagonowsky In recent weeks, COVID-19 vaccine timelines and expectations have increasingly become clearer. Moderna, a leading player, doesn’t expect to be able to file for an emergency use authorization until late November, its CEO told the Financial Times. read more By Conor Hale LabCorp has received a new emergency authorization from the FDA for a COVID-19 test that does not require the use of chemical reagents to free the coronavirus’s RNA from a sample. read more By Angus Liu Gilead's remdesivir is one of only a few drugs to show benefits in COVID-19. After a somewhat chaotic initial rollout by the U.S. government and a drop in demand since, the company is now taking distribution of the antiviral into its own hands. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner White House officials are objecting to the FDA's proposed standards for COVID-19 vaccine reviews, the WSJ reports. Regeneron and Eli Lilly wouldn't say whether President Trump might be treated for COVID with their antibody cocktails. And LabCorp now has a diagnostic test that works without extraction reagents. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Ben Adams After seven years running Merck’s R&D engine, much of which has revolved around cancer blockbuster Keytruda and, now, COVID-19 vaccines, Roger Perlmutter, M.D., Ph.D., is hitting the exit. read more By Ben Adams Nearly two months after GlaxoSmithKline’s U.S. pharma and vaccine head left the Big Pharma in the middle of it making a pandemic shot, Jack Bailey has penned a deal to lead cancer biotech G1 Therapeutics. read more |
